grant
Role of Tregs in the acquisition and maintenance of Tconv anergy in transplantation tolerance
Organization UNIVERSITY OF CHICAGOLocation CHICAGO, UNITED STATESPosted 23 Jul 2025Deadline 30 Jun 2030
NIHUS FederalResearch GrantFY2025AdenosineAlloantigenAmyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis Motor Neuron DiseaseAntibodiesAutoimmune DiseasesAutoimmune StatusAutoimmunityAutomobile DrivingBp50Brittle Diabetes MellitusCD154CD40CD40LCD40LGCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCDW40CTL A4-Ig B7 InhibitorCTLA-4-IgCTLA4-FcCTLA4-IgCTLA4-Ig immunoconjugateCancersChicagoChronicClinical TrialsCo-StimulatorCostimulatorDendritic CellsDevelopmentDisseminated SclerosisDysfunctionEpidermal Thymocyte Activating FactorFunctional disorderGehrig's DiseaseGerminal CenterGoalsGraft RejectionGrafting ProcedureHumanHumulin RIDDMIL-2IL2 ProteinImmunocompetenceImmunologic CompetenceImmunological CompetenceImmunosuppressantsImmunosuppressionImmunosuppression EffectImmunosuppressive AgentsImmunosuppressive EffectImmunosuppressive drugImmunosuppressive treatmentIn VitroInfectionInjectionsInsulinInsulin-Dependent Diabetes MellitusInterleukin 2Interleukin 2 PrecursorInterleukin IIInterleukin-2Interleukine 2Interleukine 2 PrecursorInterleukine IIJuvenile-Onset Diabetes MellitusKetosis-Prone Diabetes MellitusKidney GraftingKidney TransplantationKidney TransplantsLinkLou Gehrig DiseaseLymphocyte Mitogenic FactorMGC9013MaintenanceMalignant NeoplasmsMalignant TumorMediatingMiceMice MammalsMitogenic FactorModelingModern ManMultiple SclerosisMurineMusMutateNovolin ROrgan TransplantationOrgan TransplantsPatientsPharmaceutical AgentPharmaceuticalsPharmacologic SubstancePharmacological SubstancePhasePhysiopathologyPlatelet aggregationPropertyQOL improvementRegimenRegular InsulinRegulatory T-LymphocyteRenal GraftingRenal TransplantationRenal TransplantsRoleSolidSourceSpecificitySplenocyteStructure of germinal center of lymph nodeSudden-Onset Diabetes MellitusSuppressor CellsSuppressor-Effector T-CellsSuppressor-Effector T-LymphocytesT Suppressor CellT cell anergyT cell growth factorT-Cell DepletionT-Cell Growth FactorT-Cell Stimulating FactorT-CellsT-LymphocyteT-cell depletion therapyT-lymphocyte depletion therapyT1 DMT1 diabetesT1DT1DMT8 CellsT8 LymphocytesTNFRSF5TNFRSF5 geneTNFSF5TNFSF5 geneTRAP GeneTestingThymocyte Stimulating FactorTransplant RecipientsTransplant RejectionTransplantationTransplantation RejectionTransplantation ToleranceTregTumor Necrosis Factor Receptor Superfamily Member 5 GeneType 1 Diabetes MellitusType 1 diabetesType I Diabetes MellitusUniversitiesVeiled Cellsanergyautoimmune conditionautoimmune disorderautoimmunity diseasecardiac allograftcrosslinkcytotoxic T lymphocyte-associated antigen 4-immunoglobulindevelopmentaldonor antibodiesdonor-specific antibodydrivingexperimentexperimental researchexperimental studyexperimentsfightinghealthy volunteerheart allograftimmune suppressionimmune suppressive activityimmune suppressive agentimmune suppressive functionimmune suppressorimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimmunosuppressive substanceimmunosuppressorimprovements in QOLimprovements in quality of lifein vivoinsular sclerosisinsulin dependent diabetesinsulin dependent type 1interestjuvenile diabetesjuvenile diabetes mellitusketosis prone diabeteskidney txlymph organlymphatic organlymphoid organmalignancyneoplasm/cancernon-human primatenonhuman primateorgan allograftorgan graftorgan xenograftp50pathophysiologypermissivenesspharmaceuticalphase 1 trialphase 2 trialphase I trialphase II trialpreventpreventingprogramsquality of life improvementregulatory T-cellsside effectsocial rolesuppressor T lymphocytethromboembolic complicationsthrombosis complicationsthrombotic complicationsthymus derived lymphocytetransplanttransplant patienttype I diabetestype one diabetes
Description preview
Summary
Donor-specific transplantation tolerance is an important goal for improving the quality of life of transplant
patients, as it eliminates side-effects from chronic immunosuppression. Transient regimens that use a blocking
CD154 antibody have been shown to promote donor-specific transplantation tolerance in mice and non-human
primates.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click